P J Blanchet
Overview
Explore the profile of P J Blanchet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
482
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kato T, Montplaisir J, Blanchet P, Lund J, Lavigne G
Mov Disord
. 1999 Sep;
14(5):865-71.
PMID: 10495054
As part of a larger study, polysomnographic and audiovisual data were recorded over 2 nights in 41 subjects with a clinical diagnosis of sleep bruxism (SB). Electromyographic (EMG) events related...
12.
Bedard P, Blanchet P, Levesque D, Soghomonian J, Grondin R, Morissette M, et al.
Mov Disord
. 1999 Sep;
14 Suppl 1:4-8.
PMID: 10493397
No abstract available.
13.
Blanchet P, Konitsiotis S, Whittemore E, Zhou Z, Woodward R, Chase T
J Pharmacol Exp Ther
. 1999 Aug;
290(3):1034-40.
PMID: 10454475
The antiparkinsonian and antidyskinetic profile of two N-methyl-D-aspartate (NMDA) receptor antagonists, a competitive antagonist, (R)-4-oxo-5-phosphononorvaline (MDL 100,453), and a novel noncompetitive allosteric site antagonist, 4-hydroxy-N-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piper idi ne (Co 101244/PD 174494),...
14.
Blanchet P
Can J Neurol Sci
. 1999 Aug;
26 Suppl 2:S21-6.
PMID: 10451756
While dopamine agonists are still traditionally used as adjunct medications to improve performance and smooth out motor response complications in advanced levodopa-treated Parkinson's disease, they are increasingly used in monotherapy...
15.
Blanchet P, Fang J, Hyland K, Arnold L, Mouradian M, Chase T
Neurology
. 1999 Jul;
53(1):91-5.
PMID: 10408542
Objective: To examine the effect of 17beta-estradiol on the severity of the cardinal signs of PD in postmenopausal women. Background: Although the impact of estrogens on the manifestations of PD...
16.
Calon F, Morissette M, Goulet M, Grondin R, Blanchet P, Bedard P, et al.
Neurochem Int
. 1999 Jul;
35(1):81-91.
PMID: 10403433
The effect of various chronic dopaminergic treatments in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys on the brain gamma-aminobutyric acid type A (GABA(A)) /benzodiazepine receptor complex and GABA content was investigated in order to...
17.
Verhagen Metman L, Del Dotto P, Blanchet P, van den Munckhof P, Chase T
Amino Acids
. 1999 Jan;
14(1-3):75-82.
PMID: 9871445
In animal models of Parkinson's disease (PD), glutamate antagonists diminish levodopa (LD)-associated motor fluctuations and dyskinesias. We sought to investigate if these preclinical observations can be extended to the human...
18.
Blanchet P, Fang J, Gillespie M, Sabounjian L, Locke K, Gammans R, et al.
Clin Neuropharmacol
. 1998 Dec;
21(6):339-43.
PMID: 9844789
The contribution of dopamine D1 receptor stimulation to the motor effects of dopaminergic drugs in patients with Parkinson's disease remains undetermined. The authors of this article studied the clinical efficacy,...
19.
Blanchet P, Konitsiotis S, Hyland K, Arnold L, Pettigrew K, Chase T
Exp Neurol
. 1998 Oct;
153(2):214-22.
PMID: 9784281
The development of a validated primate model of progressive parkinsonism is a critical step in the evaluation of drugs that might halt or slow progression of Parkinson's disease. In this...
20.
Blanchet P, Konitsiotis S, Chase T
Mov Disord
. 1998 Oct;
13(5):798-802.
PMID: 9756148
The antidyskinetic potential of the glutamate NMDA receptor channel blocker amantadine was evaluated in four levodopa-primed parkinsonian monkeys using two different regimens (1.25 or 2.5 mg/kg administered subcutaneously twice daily...